News & Press Releases
Filter by:
Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.
Mintz Advises Sixth Street in $1.3 Billion Financing Supporting Paratek–Radius Combination
March 18, 2026
Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.
Mintz Represents Drone Autonomy Software Company Swarmer in Its Initial Public Offering on the Nasdaq Capital Market
March 18, 2026
Mintz represented Swarmer, Inc (Nasdaq: SWMR), a defense technology company specializing in drone autonomy software, in its initial public offering on the Nasdaq Capital Market.
Mintz Member Marc Axelbaum Named to Lawdragon’s 2026 “100 Leading AI & Legal Tech Advisors” List
March 10, 2026
Member Marc Axelbaum has been recognized for the second year in a row as one of Lawdragon’s 2026 “100 Leading AI & Legal Tech Advisors” in the White Collar, Investigations, Technology category.
Moderna, Arbutus Settle Covid Jab Dispute
March 4, 2026
Sige Gutman, Life Sciences Litigation Practice Chair, was quoted in an IAM article about global patent litigation settlement in Arbutus v. Moderna surrounding COVID-19 vaccine technology.
Mintz advised the underwriters in connection with Larimar Therapeutics’ $115 million public offering.
